|
Watson Pharmaceuticals tries to have the best of both worlds, with operations in the US generics market and the higher-profit-margin branded drug business. The company's broad generics portfolio of about 140 products includes treatments for hypertension and pain, as well as smoking cessation products, antidepressants, and oral contraceptives. Its line of about 25 branded drugs focuses on urology and nephrology; it markets its branded products, including treatments for iron deficiency anemia and overactive bladder, to specialist physicians in the US. Additionally, Watson distributes its own and third-party products to independent pharmacies and health care providers through its Anda and Valmed subsidiaries.
|
| | | Contact Information | |
Address: |
311 Bonnie Cir.
Corona, CA 92880-2882
| | Phone: | 951-493-5300 | | Fax: | 973-355-8301 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 2535.50 M | | Revenue Growth (1 yr): | 1.60% | | Employees (2008): | 5,070 | | Employee Growth (1 yr): | (-10.10%) |
|
|
Key People
| | • |
Chairman:
Andrew L. Turner
| | • |
President, CEO, and Director:
Paul M. Bisaro
| | • |
SVP and CFO:
R. Todd Joyce
|
|
|
